Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's diseasevan Kessel, S. P., Frye, A. K., El-Gendy, A. O., Castejon, M., Keshavarzian, A., van Dijk, G. & El Aidy, S., 18-Jan-2019, In : Nature Communications. 10, 1, 310.
Research output: Contribution to journal › Article › Academic › peer-review
Human gut microbiota senses its environment and responds by releasing metabolites, some of which are key regulators of human health and disease. In this study, we characterize gut-associated bacteria in their ability to decarboxylate levodopa to dopamine via tyrosine decarboxylases. Bacterial tyrosine decarboxylases efficiently convert levodopa to dopamine, even in the presence of tyrosine, a competitive substrate, or inhibitors of human decarboxylase. In situ levels of levodopa are compromised by high abundance of gut bacterial tyrosine decarboxylase in patients with Parkinson's disease. Finally, the higher relative abundance of bacterial tyrosine decarboxylases at the site of levodopa absorption, proximal small intestine, had a significant impact on levels of levodopa in the plasma of rats. Our results highlight the role of microbial metabolism in drug availability, and specifically, that abundance of bacterial tyrosine decarboxylase in the proximal small intestine can explain the increased dosage regimen of levodopa treatment in Parkinson's disease patients.
|Publication status||Published - 18-Jan-2019|
- INTESTINAL MICROBIOTA, L-DOPA, EXPRESSION, OVERGROWTH, METABOLISM, HOST, PCR
Related Press / Media
How the Microbiome Influences Drug Action - Through their effects on metabolism and immunity, bacteria in the gut affect whether medications will be effective for a given patient.
1 Media contribution
Press/Media: Public Engagement Activities › Popular
1 item of Media coverage
Press/Media: Public Engagement Activities › Professional